Kupando GmbH
Johanna Holldack is a seasoned executive with extensive leadership experience in the biotechnology and pharmaceutical sectors. Since May 2018, Holldack has served as the CEO and Founder of Kupando GmbH. Prior to this, Holldack was a Board Member at Photocure ASA from April 2017 to May 2024 and Chairman at Amal Therapeutics until its acquisition by Boehringer Ingelheim in July 2019. Additional roles include President and CEO at Trethera Corporation (2015-2017), CEO at Telormedix (2009-2015), and CEO at Borean Pharma (2003-2008). Holldack's early career included positions as COO at MediGene AG (1999-2003), VP at Chiron Corporation (1997-1999), and various roles in clinical research, project management, and regulatory affairs at Behringwerke (1990-1997). Holldack's diverse background reflects a strong commitment to advancing the life sciences industry.
This person is not in any teams
Kupando GmbH
Kupando is a pioneering biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. The Company uses its small molecule-based drug candidates to build a pipeline in several indications, in-house or via strategic partnerships, as single agent, or in combination with checkpoint inhibitors, other drugs or antigens. Its drug candidate KUP101 is the only TLR 4/7 agonist in development and consists of two small molecules, TLR4 agonist and TLR7 agonist, co-encapsulated. IND-enabling work is on-going for treatment of solid tumors and prophylaxis of infectious diseases. Kupando is a private company, seed financed by its CEO Johanna Holldack and based on technology invented by Dennis Carson’s Laboratory at the University of California San Diego. The Company’s management team brings a unique wealth of experience in business and drug development, gained in the US and Europe. Kupando is headquartered in Schoenefeld, Germany.